Despite the unprecedented success of immune checkpoint inhibitors (ICI) in several cancer types, only a subset of patients derives clinical benefit. Companies leading the charge on ICI development are faced with many questions including:
In this 45-minute webinar, we will cover how the REFS causal AI and simulation platform was used to address questions of ICI success, uncover drivers of tumor response and resistance to immune-checkpoint therapy, and uncover biomarkers that could be used to identify patients benefiting from immune-checkpoint therapy.
Craig Davis, PhD
Senior Director of Translational Oncology
Pfizer
Rahul Das, PhD
Associate Director of Precision Medicine
GNS Healthcare
Ellen Gordon, PhD
Principal, Client Solutions
GNS Healthcare